DE60118889D1 - Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs - Google Patents

Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs

Info

Publication number
DE60118889D1
DE60118889D1 DE60118889T DE60118889T DE60118889D1 DE 60118889 D1 DE60118889 D1 DE 60118889D1 DE 60118889 T DE60118889 T DE 60118889T DE 60118889 T DE60118889 T DE 60118889T DE 60118889 D1 DE60118889 D1 DE 60118889D1
Authority
DE
Germany
Prior art keywords
breast cancer
protein transferase
treatment
transferase inhibitors
farnesyl protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60118889T
Other languages
English (en)
Other versions
DE60118889T2 (de
Inventor
Peter Albert Palmer
David Horak
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of DE60118889D1 publication Critical patent/DE60118889D1/de
Application granted granted Critical
Publication of DE60118889T2 publication Critical patent/DE60118889T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60118889T 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs Expired - Lifetime DE60118889T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00200373 2000-02-04
EP00200373 2000-02-04
PCT/EP2001/001032 WO2001056552A2 (en) 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitors for treating breast cancer

Publications (2)

Publication Number Publication Date
DE60118889D1 true DE60118889D1 (de) 2006-05-24
DE60118889T2 DE60118889T2 (de) 2006-11-30

Family

ID=8170976

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60118889T Expired - Lifetime DE60118889T2 (de) 2000-02-04 2001-02-01 Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs

Country Status (13)

Country Link
US (4) US20030027839A1 (de)
EP (1) EP1255537B1 (de)
JP (1) JP5491681B2 (de)
AT (1) ATE323474T1 (de)
AU (1) AU2001233726A1 (de)
CA (1) CA2396865C (de)
CY (1) CY1105477T1 (de)
DE (1) DE60118889T2 (de)
DK (1) DK1255537T3 (de)
ES (1) ES2262626T3 (de)
PT (1) PT1255537E (de)
SI (1) SI1255537T1 (de)
WO (1) WO2001056552A2 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7342016B2 (en) 2000-08-30 2008-03-11 Schering Corporation Farnesyl protein transferase inhibitors as antitumor agents
DE60230017D1 (de) * 2001-02-15 2009-01-08 Janssen Pharmaceutica Nv Farnesyl-protein-transferase hemmer in kombination mit antiöstrogenen
MXPA04005207A (es) * 2001-11-30 2004-08-19 Schering Corp Metodos para tratar cancer utilizando un inhibidor de la farnesil proteina transferasa y agentes antineoplasticos.
US7102251B2 (en) * 2003-08-22 2006-09-05 Distributed Power, Inc. Bi-directional multi-port inverter with high frequency link transformer
CA2544421A1 (en) * 2003-11-06 2005-05-26 Schering Corporation Combination of a farnesyl transferase inhibitor with an antihormonal agent for the treatment of breast cancer
AU2004298486A1 (en) 2003-12-12 2005-06-30 Wyeth Quinolines useful in treating cardiovascular disease
WO2005089496A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20070293539A1 (en) * 2004-03-18 2007-12-20 Lansbury Peter T Methods for the treatment of synucleinopathies
WO2005089518A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Uch-l1 expression and cancer therapy
WO2005089515A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089504A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
WO2005089502A2 (en) * 2004-03-18 2005-09-29 The Brigham And Women's Hospital, Inc. Methods for the treatment of synucleinopathies
US20060194821A1 (en) * 2005-02-18 2006-08-31 The Brigham And Women's Hospital, Inc. Compounds inhibiting the aggregation of superoxide dismutase-1
EP1968591A4 (de) 2005-12-23 2010-02-17 Link Medicine Corp Behandlung von synucleinopathien
US8232402B2 (en) * 2008-03-12 2012-07-31 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
EP2370436A1 (de) * 2008-11-13 2011-10-05 Link Medicine Corporation Azachinolinonderivate und deren verwendungen
US20100331363A1 (en) * 2008-11-13 2010-12-30 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
US20110060005A1 (en) * 2008-11-13 2011-03-10 Link Medicine Corporation Treatment of mitochondrial disorders using a farnesyl transferase inhibitor
EP2288195B1 (de) * 2009-08-20 2019-10-23 Samsung Electronics Co., Ltd. Verfahren und Vorrichtung zum Betreiben einer Basisstation in einem drahtlosen Kommunikationssystem
EP2909189B8 (de) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Heteroarylverknüpfte chinolinyl-modulatoren von ror-gamma-t
WO2014062658A1 (en) 2012-10-16 2014-04-24 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of ror-gamma-t
EP2909193B1 (de) 2012-10-16 2017-04-19 Janssen Pharmaceutica NV Phenylgebundene chinolinylmodulatoren von ror-gamma-t
US9403816B2 (en) 2013-10-15 2016-08-02 Janssen Pharmaceutica Nv Phenyl linked quinolinyl modulators of RORγt
US10555941B2 (en) 2013-10-15 2020-02-11 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
US9328095B2 (en) 2013-10-15 2016-05-03 Janssen Pharmaceutica Nv Heteroaryl linked quinolinyl modulators of RORgammat
AU2014334616A1 (en) 2013-10-15 2016-04-28 Janssen Pharmaceutica Nv Quinolinyl modulators of RORyt
US9284308B2 (en) 2013-10-15 2016-03-15 Janssen Pharmaceutica Nv Methylene linked quinolinyl modulators of RORγt
US9346782B2 (en) 2013-10-15 2016-05-24 Janssen Pharmaceutica Nv Alkyl linked quinolinyl modulators of RORγt
EP3385395B9 (de) 2015-08-17 2020-05-20 Kura Oncology, Inc. Verfahren zur behandlung von krebspatienten mit farnesyl-transferase-inhibitoren
WO2018085518A2 (en) 2016-11-03 2018-05-11 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE321757T1 (de) * 1995-12-08 2006-04-15 Janssen Pharmaceutica Nv (imidazol-5-yl)methyl-2-chinolinonderivate als farnesyl protein transferase inhibitoren
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US5994364A (en) * 1996-09-13 1999-11-30 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
KR100520401B1 (ko) * 1997-04-25 2005-10-12 얀센 파마슈티카 엔.브이. 파네실 트랜스퍼라제 억제작용을 갖는 퀴나졸리논
US5925639A (en) * 1997-06-17 1999-07-20 Schering Corporation Keto amide derivatives useful as farnesyl protein transferase inhibitors
US5852034A (en) * 1997-06-17 1998-12-22 Schering Corporation Benzo(5,6)cycloheptapyridine cyclic ureas and lactams useful as farnesyl protein transferase inhibitors
US6096757A (en) * 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
CA2336448A1 (en) * 1998-07-02 2000-01-13 Christopher J. Dinsmore Inhibitors of prenyl-protein transferase
EE04582B1 (et) * 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine radiosensibiliseerimisomadustega farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud kasutamiseks vähi kiiritusravis
CA2341739C (en) * 1998-08-27 2005-07-12 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
SI1140935T1 (en) * 1998-12-23 2003-10-31 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
CA2397558A1 (en) * 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
AU2001244166A1 (en) * 2000-02-29 2001-09-12 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitor combinations with further anti-cancer agents
US20020022633A1 (en) * 2000-06-30 2002-02-21 Williams Theresa M. Inhibitors of prenyl-protein transferase

Also Published As

Publication number Publication date
EP1255537A2 (de) 2002-11-13
US20110098318A1 (en) 2011-04-28
ES2262626T3 (es) 2006-12-01
DK1255537T3 (da) 2006-08-21
EP1255537B1 (de) 2006-04-19
WO2001056552A2 (en) 2001-08-09
PT1255537E (pt) 2006-09-29
JP5491681B2 (ja) 2014-05-14
US20090018164A1 (en) 2009-01-15
WO2001056552A3 (en) 2002-04-25
SI1255537T1 (sl) 2006-10-31
AU2001233726A1 (en) 2001-08-14
CY1105477T1 (el) 2010-04-28
JP2003521509A (ja) 2003-07-15
US20030027839A1 (en) 2003-02-06
ATE323474T1 (de) 2006-05-15
US20040192726A1 (en) 2004-09-30
CA2396865C (en) 2009-04-14
CA2396865A1 (en) 2001-08-09
DE60118889T2 (de) 2006-11-30

Similar Documents

Publication Publication Date Title
DE60118889D1 (de) Farnesyl protein transferase inhibitoren zur behandlung von brustkrebs
DE60105295D1 (de) Chinazolinderivate zur behandlung von tumoren
DE60130976D1 (de) Dosierschema enthaldend farnesyl protein transferase inhibitoren für die behandlung von krebs
ATE253914T1 (de) Farnesyl protein transferase inhibitoren zur behandlung von arthropathien
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE60030889D1 (de) Verwendung von egfr tyrosine kinase hemmern zur behandlung von brustkrebs
ATE323490T1 (de) Farnesyl-protein-transferasehemmer zur behandlung der entzündlichen darmerkrankung
ATE412646T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60215682D1 (de) AZAOXOINDOL DERIVATE ALS Trk PROTEIN KINASE HEMMSTOFFE ZUR BEHANDLUNG VON KREBS UND CHRONISCHEM SCHMERZ
DE60021381D1 (de) Chinonverbindungen zur behandlung von krankheiten
DK1315506T3 (da) Phospholipidderivater af valproinsyre og blandinger deraf
ATE438618T1 (de) Inhibitoren von humanem adam-10
ATE360442T1 (de) Verfahren und zusammensetzungen zur behandlung von hyperproliferativen zuständen
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
ATE302002T1 (de) Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit
DE602004028574D1 (de) Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie
DE602004021363D1 (de) Imidazotriazin verbindungen zur behandlung von krebserkrankungen
DE60123138D1 (de) Verwendung von progesteronrezeptorhemmern zur behandlung von steroid-resistentem brustkrebs
DE60131968D1 (de) PYRANOÄ2,3-cÜIMIDAZOÄ1,2-aÜPYRIDIN-DERIVATE ZUR BEHANDLUNG VON GASTROINTESTINALEN ERKRANKUNGEN
DE60142786D1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
DE60220825D1 (de) Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
DE60334289D1 (de) Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen
DE60229047D1 (de) Einzeldosis aromatase hemmer zur behandlung von unfruchtbarkeit
DE60326348D1 (de) Makrozyclen zur behandlung von krebserkrankungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition